These innovative molecules represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose https://cecilyjhrx204878.ziblogs.com/39406198/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide